Article

Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patients

2023-12-19

Abstract excerpt

Chronic Myeloid Leukemia, resulting due to chromosomal aberration t(9;22) through formation of oncogenic BCR-ABL fusion oncogene. Modern BCR-ABL inhibitors, called TKIs, have revolutionized CML treatment. CML has three stages: chronic, accelerated, and blast crisis. TKIs work well in CP-CML, where patients survive as long as the normal population, but they don’t work in AP- and BC-CML. Even with advances in treatm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 677caaf5-8b4b-5932-8b9f-ad68c221abf7
DOI: 10.1101/2023.12.19.23300103

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patientsDOI 10.1101/2023.12.19.23300103Read

Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia PatientsSemantic proximity Read

Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase CML.Semantic proximity Read

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid LeukemiaSemantic proximity Read

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity Read

Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CMLSemantic proximity Read

Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI eraSemantic proximity Read

Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.Semantic proximity Read

[Analysis of Bone Marrow and Peripheral Blood Cytological Characteristics and Prognostic Research in FLT3-ITD mutated Acute Myeloid Leukemia].Semantic proximity Read

Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CMLSemantic proximity Read

[Clinical Value of Detecting ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Based on High-Throughput Sequencing Technology].Semantic proximity Read

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read

Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity Read